home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605a.zip
/
M9650128.TXT
< prev
next >
Wrap
Text File
|
1996-03-09
|
3KB
|
45 lines
Document 0128
DOCN M9650128
TI Immunization with envelope subunit vaccine products elicits neutralizing
antibodies against laboratory-adapted but not primary isolates of human
immunodeficiency virus type 1. The National Institute of Allergy and
Infectious Diseases AIDS Vaccine Evaluation Group.
DT 9605
AU Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH;
Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ;
Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS; Division of
Retrovirology, Walter Reed Army Institute of; Research, Henry M. Jackson
Foundation for the Advancement of; Military Medicine, Rockville, MD
20850, USA.
SO J Infect Dis. 1996 Feb;173(2):340-8. Unique Identifier : AIDSLINE
MED/96162091
AB Phase I studies of volunteers not infected with human immunodeficiency
virus type 1 (HIV-1) have shown that immunization with envelope subunit
vaccine products elicits antibodies that neutralize laboratory-adapted
(prototype) HIV-1 strains in vitro. Prototype strains are adapted to
grow in continuous (neoplastic) cell lines and are more susceptible to
neutralization than are primary isolates cultured in human peripheral
blood mononuclear cells. In this study, 50 sera from nine phase I
vaccine trials and 16 from HIV-1-infected persons were evaluated for
neutralizing antibody activity against 3 laboratory-adapted and 5
primary HIV-1 isolates. Of 50 sera, 49 neutralized at least 1 of the
prototype strains; however, none displayed neutralizing activity against
primary isolates of HIV-1. Serum from most HIV-1-infected persons
neutralized both laboratory-adapted and primary HIV-1 isolates. These
data demonstrate a qualitative, or large quantitative, difference in the
neutralizing antibody response induced by envelope subunit vaccination
and natural HIV-1 infection.
DE Adolescence Adult AIDS Vaccines/*ADMINISTRATION & DOSAGE Cells,
Cultured Double-Blind Method Female Gene Products, env/*IMMUNOLOGY
Human HIV Antibodies/*IMMUNOLOGY HIV Envelope Protein
gp120/*IMMUNOLOGY HIV Infections/*IMMUNOLOGY/VIROLOGY
HIV-1/*IMMUNOLOGY/ISOLATION & PURIF *Immunization Leukocytes,
Mononuclear/VIROLOGY Male Middle Age Neutralization Tests Protein
Precursors/*IMMUNOLOGY Support, U.S. Gov't, Non-P.H.S. Support, U.S.
Gov't, P.H.S. Virus Cultivation CLINICAL TRIAL CLINICAL TRIAL, PHASE
I JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).